Obermatt
See Similar Stocks →

Hanmi Pharmaceutical

KSC:128940 · KR7128940004
PharmaceuticalsMedium

360

76
EV / EBIT37
Price / Owner Earnings41
Owner Earnings Yield69
Dividend Yield67
Price/Sales15
EV / Gross Profit50
Price/Book9
Return on Capital59
Cash Return on Capital69
Return on Equity62
EBIT Margin34
Gross Profitability57
Cash Conversion46
Accruals43
Owner Earnings Margin57
Sales growth37
Profit Growth83
Long-Term EPS Growth82
Owner Earnings Growth59
Reinvestment39
Price momentum99
Debt load56
Refinancing14
Debt Payback34
Liquidity70
Analyst ratings63
Opinion Changes37
Price Target Upside63
Market mood43
Value Creation18/20strong value creator
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

Hanmi Pharmaceutical generates returns well above its cost of capital, the foundation of durable shareholder value.

Profile

CountrySouth Korea
IndustryPharmaceuticals
SizeMedium
TypePublic Company
ExchangeKOSE
Employees287
Websitehanmi.co.kr
ISINKR7128940004
Last UpdateApr 2, 2026
Indices
KOSPI (South Korea)
Themes
UrologyOncologyObesityHealth Care

Description

Analysis

Middle-of-the-road

Hanmi Pharm. Co., Ltd. is a middle-of-the-road business: neither the economics nor the price stand out from the peer group.

The price is fair. You pay 22.0× its owner earnings: the cash an owner could take out each year, which is in the historically fair zone. At today's price, the market is assuming roughly 8% yearly growth; analysts expect 22%. The price, in other words, assumes less than the experts do.

The trajectory is moderate and the balance sheet is sturdy. The company scores 18/20 on our value-creation score: strong value creator.

Nothing is flagged here: no red or amber gates, no divergence between profits and cash. That is itself information: the numbers are straightforward. As always: this describes the company's numbers; it is not a recommendation.

360° rank · history

1007550250
34
2023202420252026

All-time high

51

Mar 2026

All-time low

10

Jan 2025

Average rank

32

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
15
28
30
39
Price/Earnings
24
30
26
14
Price/Book
9
19
12
14
Dividend Yield
67
20
23
17
Value (overall)
16
16
18
15

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Hanmi Pharmaceutical with its peers
Shionogi
TYO:4507
70
CountryJapan
IndustryPharmaceuticals
SizeX-Large
Full Stock Analysis →
Lotus Pharmaceutical
TAI:1795
19
CountryTaiwan
IndustryPharmaceuticals
SizeMedium
Full Stock Analysis →
JW Pharmaceutical
KSC:001060
95
CountrySouth Korea
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
Dong-A Socio
KSC:000640
85
CountrySouth Korea
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
Kwangdong Pharmaceutical
KSC:009290
80
CountrySouth Korea
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
Mayne Pharma
ASX:MYX
55
CountryAustralia
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →